111 related articles for article (PubMed ID: 37573784)
1. No Survival Differences among Germ-Cell Cancer Patients from Urban and Rural Areas.
Hoch D; Helnwein S; Adrizzone D; Lorch A; Fankhauser C; Hermanns T; Thalmann G; Beyer J
Oncol Res Treat; 2023; 46(10):433-437. PubMed ID: 37573784
[TBL] [Abstract][Full Text] [Related]
2. Perioperative complications and oncological outcomes of post-chemotherapy retroperitoneal lymph node dissection in patients with germ cell cancer at two high-volume university centres in Switzerland - a retrospective chart review.
Notarfrancesco M; Fankhauser CD; Lorch A; Ardizzone D; Helnwein S; Hoch D; Hermanns T; Thalmann G; Beyer J
Swiss Med Wkly; 2023 Apr; 153():40053. PubMed ID: 37080191
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study.
Hentrich MU; Bower M; Daugaard G; Dieing A; Bickel M; Berretta M; Lesmeister F; Jurinovic V; Stoehr A; Heinzelbecker J; Krznaric I; Dieckmann KP; Necchi A; Maroto Rey P; Rockstroh JK; Brito M; Pfister D; Hoffmann C
Cancer; 2022 Jan; 128(2):260-268. PubMed ID: 34592009
[TBL] [Abstract][Full Text] [Related]
4. Low Survival in Poor Prognosis Metastatic Germ Cell Cancer in Belarus.
Rolevich AI; Borodin DM; Rabcheuski AN; Ivanitskaya TA; Semenov SA; Artsiushkevich LV; Sukalinskaya AV; Zhavrid EA; Krasny SA; Konoplya NE; Polyakov SL
JCO Glob Oncol; 2021 Jan; 7():63-71. PubMed ID: 33434070
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
[TBL] [Abstract][Full Text] [Related]
6. The clinical features and management of testicular germ cell tumours in patients aged 60 years and older.
Wheater MJ; Manners J; Nolan L; Simmonds PD; Hayes MC; Mead GM
BJU Int; 2011 Dec; 108(11):1794-9. PubMed ID: 21627751
[TBL] [Abstract][Full Text] [Related]
7. Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma.
Fischer S; Tandstad T; Cohn-Cedermark G; Thibault C; Vincenzi B; Klingbiel D; Albany C; Necchi A; Terbuch A; Lorch A; Aparicio J; Heidenreich A; Hentrich M; Wheater M; Langberg CW; Ståhl O; Fankhauser CD; Hamid AA; Koutsoukos K; Shamash J; White J; Bokemeyer C; Beyer J; Gillessen S;
J Clin Oncol; 2020 Apr; 38(12):1322-1331. PubMed ID: 31877087
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
Fenner M; Oing C; Dieing A; Gauler T; Oechsle K; Lorch A; Hentrich M; Kopp HG; Bokemeyer C; Honecker F
J Cancer Res Clin Oncol; 2019 Mar; 145(3):717-723. PubMed ID: 30232558
[TBL] [Abstract][Full Text] [Related]
10. Surveillance after Complete Response to First-Line Chemotherapy in Patients with Metastatic Nonseminomatous Germ Cell Tumor.
King JM; Althouse S; Cary C; Masterson T; Foster RS; Ashkar R; Hanna NH; Einhorn LH; Adra N
J Urol; 2022 Sep; 208(3):641-649. PubMed ID: 35674780
[TBL] [Abstract][Full Text] [Related]
11. Oral versus intravenous fluoropyrimidines for colorectal cancer.
Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
[TBL] [Abstract][Full Text] [Related]
12. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.
Albany C; Adra N; Snavely AC; Cary C; Masterson TA; Foster RS; Kesler K; Ulbright TM; Cheng L; Chovanec M; Taza F; Ku K; Brames MJ; Hanna NH; Einhorn LH
Ann Oncol; 2018 Feb; 29(2):341-346. PubMed ID: 29140422
[TBL] [Abstract][Full Text] [Related]
13. First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment : A comprehensive review compiled by the German Testicular Cancer Study Group.
Pfister D; Oechsle K; Schmidt S; Busch J; Bokemeyer C; Heidenreich A; Heinzelbecker J; Ruf C; Winter C; Zengerling F; Kliesch S; Albers P; Oing C
World J Urol; 2022 Dec; 40(12):2853-2861. PubMed ID: 35226138
[TBL] [Abstract][Full Text] [Related]
14. The importance of the dose of etoposide in the initial treatment of metastatic germ cell tumors and advances in management of patients that relapse.
Marwaha S; Venner PM; North SA
Can J Urol; 2007 Oct; 14(5):3692-6. PubMed ID: 17949524
[TBL] [Abstract][Full Text] [Related]
15. Characterizing Urban-Rural Differences in Colon Cancer Outcomes: A Population-based Analysis Based on Travel Distance to Cancer Center.
Bosma NA; Tilley D; Batra A; Cheung WY
Am J Clin Oncol; 2020 Jul; 43(7):531-535. PubMed ID: 32324599
[TBL] [Abstract][Full Text] [Related]
16. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
17. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
[TBL] [Abstract][Full Text] [Related]
19. Management of Late Relapses After Chemotherapy in Testicular Cancer: Optimal Outcomes with Dose-intense Salvage Chemotherapy and Surgery.
Alifrangis C; Lucas O; Benafif S; Ansell W; Greenwood M; Smith S; Wilson P; Thomas B; Rudman S; Mazhar D; Berney D; Shamash J
Eur Urol Focus; 2021 Jul; 7(4):835-842. PubMed ID: 32381397
[TBL] [Abstract][Full Text] [Related]
20. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance.
Kollmannsberger C; Tandstad T; Bedard PL; Cohn-Cedermark G; Chung PW; Jewett MA; Powles T; Warde PR; Daneshmand S; Protheroe A; Tyldesley S; Black PC; Chi K; So AI; Moore MJ; Nichols CR
J Clin Oncol; 2015 Jan; 33(1):51-7. PubMed ID: 25135991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
